BCIQ Profiles

Company Profile Report

Preparing to strike

How Ascletis will use its $100M B round to expand beyond HCV

With $100 million in hand Ascletis BioScience Co. Ltd. is poised to repeat what it has done in HCV by hunting for new liver therapies for the China market.

On Jan. 3, Ascletis closed an untranched $100

Read the full 364 word article

How to gain access

Continue reading with a
two-week free trial.